

Title (en)

HUMAN LEUKOCYTE 12-LIPOXYGENASE AND ITS ROLE IN THE PATHOGENESIS OF DISEASE STATES

Title (de)

12-LIPOXYGENASE AUS MENSCHLICHEN LEUKOZYTEN UND IHRE WIRKUNG IN DER KRANKHEITSZUSTÄNDEN-PATHOGENESE

Title (fr)

12-LIPOXYGENASE LEUCOCYTAIRE HUMAINE ET SON ROLE DANS LA PATHOGENESE D'ETATS PATHOLOGIQUES

Publication

**EP 0824583 A1 19980225 (EN)**

Application

**EP 96913354 A 19960503**

Priority

- US 9606328 W 19960503
- US 43468195 A 19950504

Abstract (en)

[origin: WO9634943A1] Evidence for the presence of a human leukocyte type of 12-LO enzyme and its role in the pathogenesis of several major disease states or processes, including atherosclerosis, breast cancer, autoimmune and inflammatory disease, diabetic vascular and kidney disease and insulin resistance is described. Mediation, including the blockage of the human leukocyte 12-LO expression or enzyme activation, provides novel treatment to prevent or ameliorate these disease states.

IPC 1-7

**C12N 9/02**; C12Q 1/26; A61K 31/00; A61K 31/155; A61K 31/35; A61K 31/44; A61K 31/20; A61K 38/20; A61K 38/18; A61K 33/10

IPC 8 full level

**A61K 31/00** (2006.01); **A61K 31/045** (2006.01); **A61K 31/05** (2006.01); **A61K 31/155** (2006.01); **A61K 31/195** (2006.01); **A61K 31/20** (2006.01); **A61K 31/201** (2006.01); **A61K 31/202** (2006.01); **A61K 31/35** (2006.01); **A61K 31/352** (2006.01); **A61K 31/44** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/575** (2006.01); **A61K 33/06** (2006.01); **A61K 38/00** (2006.01); **A61K 38/08** (2006.01); **A61K 38/18** (2006.01); **A61K 38/20** (2006.01); **A61K 38/46** (2006.01); **A61K 45/00** (2006.01); **A61K 48/00** (2006.01); **A61P 3/00** (2006.01); **A61P 3/10** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 35/04** (2006.01); **A61P 37/00** (2006.01); **C12N 9/02** (2006.01); **C12N 9/99** (2006.01); **C12Q 1/26** (2006.01); **G01N 33/573** (2006.01); **G01N 33/68** (2006.01)

CPC (source: EP)

**A61K 31/00** (2013.01); **A61K 31/045** (2013.01); **A61K 31/05** (2013.01); **A61K 31/155** (2013.01); **A61K 31/195** (2013.01); **A61K 31/20** (2013.01); **A61K 31/35** (2013.01); **A61K 31/352** (2013.01); **A61K 31/44** (2013.01); **A61K 31/4439** (2013.01); **A61K 31/575** (2013.01); **A61K 38/085** (2013.01); **A61K 38/1858** (2013.01); **A61K 38/2006** (2013.01); **A61P 3/00** (2017.12); **A61P 3/10** (2017.12); **A61P 9/00** (2017.12); **A61P 9/10** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 35/04** (2017.12); **A61P 37/00** (2017.12); **C12N 9/0069** (2013.01); **C12Q 1/26** (2013.01); **G01N 33/6893** (2013.01); **G01N 2333/90241** (2013.01); **G01N 2800/042** (2013.01)

Citation (search report)

See references of WO 9634943A1

Designated contracting state (EPC)

DE FR GB

DOCDB simple family (publication)

**WO 9634943 A1 19961107**; AU 5637796 A 19961121; AU 706241 B2 19990610; CA 2220156 A1 19961107; EP 0824583 A1 19980225; JP H115111004 A 19990928

DOCDB simple family (application)

**US 9606328 W 19960503**; AU 5637796 A 19960503; CA 2220156 A 19960503; EP 96913354 A 19960503; JP 53357096 A 19960503